Last reviewed · How we verify
Poteligeo
At a glance
| Generic name | Poteligeo |
|---|---|
| Also known as | Mogamulizumab |
| Sponsor | Kyowa Kirin Pharmaceutical Development Ltd |
| Target | C-C chemokine receptor type 4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Mycosis fungoides
- Peripheral T-cell lymphoma
- Primary cutaneous T-cell lymphoma
Common side effects
- Rash (including drug eruption)
- Infusion related reactions
- Fatigue
- Diarrhea
- Upper respiratory tract infection
- Musculoskeletal pain
- Skin infection
- Pyrexia
- Nausea
- Edema
- Thrombocytopenia
- Headache
Serious adverse events
- Fatal adverse reactions
- Pneumonia
- Sepsis
- Pyrexia
- Skin infection
- Hepatitis
- Pneumonitis
- Rash
- Infusion related reaction
- Lower respiratory tract infection
Key clinical trials
- Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) (EARLY_PHASE1)
- Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma (PHASE1)
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas (PHASE2)
- Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment (PHASE1, PHASE2)
- Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma (PHASE2)
- Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
- Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Poteligeo CI brief — competitive landscape report
- Poteligeo updates RSS · CI watch RSS
- Kyowa Kirin Pharmaceutical Development Ltd portfolio CI